| Literature DB >> 26581748 |
Bruno A Randi1, Daniel A Ninomiya2, Elizabeth L Nicodemo3, Beatriz C Lopes4, Eduardo R Cançado5, Anna S Levin6.
Abstract
BACKGROUND: Bleeding from gastric varices has high mortality rate, and obliteration using N-butyl-2-cyanoacrylate is the treatment of choice. Recurrent bacteremia is rarely reported following the procedure. We aimed to report a case of recurrent bacteremia after N-butyl-2-cyanoacrylate treatment and to review published cases. CASE PRESENTATION AND REVIEW: In May 2014, a 43-year-old Brazilian male presented with lower gastrointestinal bleeding. Endoscopy showed active bleeding from gastric varix. Injection of N-butyl-2-cyanoacrylate was performed and the patient was discharged. Over the next 4 months he presented with three episodes of bacteremia with severe sepsis and no identifiable focus of infection. Oral prophylaxis was initiated in September 2014 and he has remained free of bacteremia. Six other cases of recurrent bacteremia following sclerosis with N-butyl-2-cyanoacrylate were reported in the literature. All patients had portal hypertension and bleeding from gastric varices. Average age of patients was 55.7 years and the median time from endoscopic procedure to the first episode of bacteremia was 105 days (range 14-365). The mean number of episodes of bacteremia per patient was 2.5.Entities:
Mesh:
Substances:
Year: 2015 PMID: 26581748 PMCID: PMC4652425 DOI: 10.1186/s13104-015-1679-6
Source DB: PubMed Journal: BMC Res Notes ISSN: 1756-0500
Characteristics of seven patients with recurrent bacteremia following the injection of N-butyl-2-cyanoacrylate for the treatment of bleeding gastric varices
| Case number | Gender | Age (years) | Underlying diseases | Time from application of | Number of episodes with positive blood culture | Microorganism isolated from blood culture | Findings of the investigation | Treatment | Outcome | Long term antimicrobial secondary “prophylaxis” | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Wahl P, 2004 [ | 1 | Male | 60 | Alcoholic liver cirrhosis + portal hypertension | 3.5 months | 3 | 1st episode: | No significant findings | 1st episode: IVb ceftriaxone (duration not reported) | Death | No |
| 2 | Male | 57 | Alcoholic liver cirrhosis + portal hypertension | 12 months | 2 |
| Inflammation around cyanoacrylate plug | IVb ceftriaxone (duration not reported) | Cure | Yes (oral ciprofloxacin for 3 months) | |
| Wright G, 2009 [ | 3 | Male | 38 | Alcoholic liver cirrhosis + portal hypertension | 6 months | 3 | ESBLa-producing | Cyanoacrylate embolism to inferior vena cava and left renal vein | IVb ertapenem for 6 months | Cure | No |
| Galperine T, 2009 [ | 4 | Male | 69 | Idiopathic portal thrombosis + portal hypertension | 6 months | 2 |
| Abscess contiguous to cyanoacrylate material | IVb clindamycin + impenem for 2 weeks | Cure | Yes (oral Cefuroxime for 3 months) |
| 5 | Male | 46 | Hepatitis B cirrhosis + portal hypertension + HIV | 2 weeks | 3 |
| Cyanoacrylate embolism to spleen and left renal vein | IVb piperacilin/tazobactam for 2 weeks | Cure | Yes (oral amoxicillin/clavulanate for 6 weeks and then IVb ceftriaxone for 3 months) | |
| Reuken PA, 2012 [ | 6 | Male | 77 | Alcoholic liver cirrhosis + portal hypertension | 3 months | 2 | ESBLa-producing | Incomplete obliteration of gastric varices | IVb imipenem (duration not reported) + surgery with cardia resection + spleno-renal shunt | Death | No |
| Present case | 7 | Male | 43 | Auto immune hepatitis and cirrhosis + portal hypertension + diabetes mellitus | 2 months | 3 | 1st episode: | Cyanoacrilate embolism to perigastric and cardioprhenic veins | 1st episode: IVb ceftriaxone for 7 days | Cure | Yes (amoxicillin/clavulanate- indefinitely) |
a ESBL extended spectrum beta-lactamase
b IV intravenous